| Brian Uhlir, CRNA | |
|
250 Hospital Pl, Soldotna, AK 99669-6999 | |
| (907) 714-4529 | |
| (907) 714-4529 |
| Full Name | Brian Uhlir |
|---|---|
| Gender | Male |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 14 Years |
| Location | 250 Hospital Pl, Soldotna, Alaska |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093031874 | NPI | - | NPPES |
| 206095 | Other | AK | AK LICENSE |
| 101117 | Other | NE | NE STATE LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 101117 (Nebraska) | Secondary |
| 367500000X | Nurse Anesthetist, Certified Registered | 206095 (Alaska) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Central Peninsula General Hospital | Soldotna, AK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Central Peninsula General Hospital Inc | 4587552575 | 85 |
News Archive
For every person living with and affected by MS there is a unique story about how they move forward with their lives. That is why the National Multiple Sclerosis Society is launching We Keep Moving, a viewer-driven reality campaign that will capture these stories and perspectives through online videos that chronicle how people across the country keep moving forward while living with MS
Hot on the heels of the FDA's rejection of Inamed's attempt to have its Silicone-gel breast implants re-instated, a second manufacturer Mentor has also tried to convince sceptical federal health advisers to the Food and Drug Administration to lift a 13-year near-ban on silicone-gel breast implants.
Salix Pharmaceuticals, Ltd. today announced that NASDAQ has halted trading of the Company's common stock this morning. The Gastrointestinal Drugs Advisory Committee of the FDA is meeting today to discuss the efficacy and safety of the New Drug Application (NDA) for XIFAXAN® (rifaximin) Tablets, 550 mg for the maintenance of remission of hepatic encephalopathy.
Primary Ciliary Dyskinesia is mainly a lung disease: a rare, genetically heterogeneous disorder resulting from dysfunction of small hair-like organelles (cilia) that clean the upper and lower airways. It can also affect multiple organs beside the respiratory system, and may cause serious impairment and lower quality of life. Its prevalence is estimated to be about 1 in 16,000.
A team at Scripps Research in Florida has discovered a biological system that manages cells' response to opioid drug exposure. The unexpected discovery offers new ideas for improving the safety of the one of the most effective, and most abused, group of pain medications.
› Verified 3 days ago
| Entity Name | Central Peninsula General Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528062429 PECOS PAC ID: 4587552575 Enrollment ID: O20040310000598 |
News Archive
For every person living with and affected by MS there is a unique story about how they move forward with their lives. That is why the National Multiple Sclerosis Society is launching We Keep Moving, a viewer-driven reality campaign that will capture these stories and perspectives through online videos that chronicle how people across the country keep moving forward while living with MS
Hot on the heels of the FDA's rejection of Inamed's attempt to have its Silicone-gel breast implants re-instated, a second manufacturer Mentor has also tried to convince sceptical federal health advisers to the Food and Drug Administration to lift a 13-year near-ban on silicone-gel breast implants.
Salix Pharmaceuticals, Ltd. today announced that NASDAQ has halted trading of the Company's common stock this morning. The Gastrointestinal Drugs Advisory Committee of the FDA is meeting today to discuss the efficacy and safety of the New Drug Application (NDA) for XIFAXAN® (rifaximin) Tablets, 550 mg for the maintenance of remission of hepatic encephalopathy.
Primary Ciliary Dyskinesia is mainly a lung disease: a rare, genetically heterogeneous disorder resulting from dysfunction of small hair-like organelles (cilia) that clean the upper and lower airways. It can also affect multiple organs beside the respiratory system, and may cause serious impairment and lower quality of life. Its prevalence is estimated to be about 1 in 16,000.
A team at Scripps Research in Florida has discovered a biological system that manages cells' response to opioid drug exposure. The unexpected discovery offers new ideas for improving the safety of the one of the most effective, and most abused, group of pain medications.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Brian Uhlir, CRNA 988102 Nebraska Medical Ctr, Omaha, NE 68198-8102 Ph: (402) 559-9800 | Brian Uhlir, CRNA 250 Hospital Pl, Soldotna, AK 99669-6999 Ph: (907) 714-4529 |
News Archive
For every person living with and affected by MS there is a unique story about how they move forward with their lives. That is why the National Multiple Sclerosis Society is launching We Keep Moving, a viewer-driven reality campaign that will capture these stories and perspectives through online videos that chronicle how people across the country keep moving forward while living with MS
Hot on the heels of the FDA's rejection of Inamed's attempt to have its Silicone-gel breast implants re-instated, a second manufacturer Mentor has also tried to convince sceptical federal health advisers to the Food and Drug Administration to lift a 13-year near-ban on silicone-gel breast implants.
Salix Pharmaceuticals, Ltd. today announced that NASDAQ has halted trading of the Company's common stock this morning. The Gastrointestinal Drugs Advisory Committee of the FDA is meeting today to discuss the efficacy and safety of the New Drug Application (NDA) for XIFAXAN® (rifaximin) Tablets, 550 mg for the maintenance of remission of hepatic encephalopathy.
Primary Ciliary Dyskinesia is mainly a lung disease: a rare, genetically heterogeneous disorder resulting from dysfunction of small hair-like organelles (cilia) that clean the upper and lower airways. It can also affect multiple organs beside the respiratory system, and may cause serious impairment and lower quality of life. Its prevalence is estimated to be about 1 in 16,000.
A team at Scripps Research in Florida has discovered a biological system that manages cells' response to opioid drug exposure. The unexpected discovery offers new ideas for improving the safety of the one of the most effective, and most abused, group of pain medications.
› Verified 3 days ago
Theresa Chihuly, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 250 Hospital Pl, Soldotna, AK 99669 Phone: 907-714-4404 | |
Amanda Lee, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 250 Hospital Pl, Soldotna, AK 99669 Phone: 907-714-4404 Fax: 907-262-2745 | |
Mrs. Sarah Holly Godsey, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 250 Hospital Pl, Soldotna, AK 99669 Phone: 907-714-4404 | |
Rachel P Neuendorf, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 250 Hospital Pl, Soldotna, AK 99669 Phone: 907-714-4502 Fax: 907-714-4696 | |
Brandi Lee Peck, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 250 Hospital Pl, Soldotna, AK 99669 Phone: 907-714-4404 | |
Mrs. Judy Lee Rohl, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 250 Hospital Pl, Soldotna, AK 99669 Phone: 907-714-4404 |